Related Experiment Video
Updated: Feb 12, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal
Robert Edfors1,2, Anders Sahlén1,2,3, Karolina Szummer1,2
1Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
Insights
Ticagrelor use in acute myocardial infarction (MI) patients showed a lower risk of death, MI, or stroke compared to clopidogrel across all estimated glomerular filtration rate (eGFR) levels. However, ticagrelor was associated with increased bleeding risk, particularly in patients with reduced eGFR.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Acute myocardial infarction (MI) management often involves P2Y12 inhibitors like ticagrelor and clopidogrel.
- Patient outcomes may vary based on renal function, specifically estimated glomerular filtration rate (eGFR).
Purpose of the Study:
- To analyze the comparative effectiveness and safety of ticagrelor versus clopidogrel in acute MI survivors.
- To stratify outcomes based on patient estimated glomerular filtration rate (eGFR) levels.
Main Methods:
- Utilized data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease registry.
- Employed adjusted Cox proportional hazards models to assess the association between ticagrelor and clopidogrel with composite outcomes (death, MI, stroke) and bleeding rehospitalization at one year.
- Stratified analyses were performed across eGFR categories: >60, 30-60, and <30 mL/min/1.73m².
Main Results:
- In a cohort of 45,206 MI patients, ticagrelor was associated with a lower adjusted 1-year risk of death, MI, or stroke compared to clopidogrel across all eGFR strata (eGFR>60: HR 0.87; eGFR 30-60: HR 0.82).
- Ticagrelor use was linked to a higher risk of bleeding rehospitalization, with a more pronounced effect observed in patients with eGFR <30 mL/min/1.73m² (HR 1.79).
- No significant interaction was found between treatment and eGFR for either the composite outcome or bleeding risk.
Conclusions:
- Ticagrelor demonstrates a reduced risk of major adverse cardiovascular events compared to clopidogrel in acute MI patients, irrespective of renal function.
- Clinicians should exercise caution regarding increased bleeding risk with ticagrelor, especially in patients with severely impaired renal function (eGFR <30 mL/min/1.73m²).
- The findings support individualized treatment decisions considering both efficacy and bleeding risk in MI patients with varying degrees of renal impairment.
Objectives:
We aimed to analyse outcomes of ticagrelor and clopidogrel stratified by estimated glomerular filtration rate (eGFR) in a large unselected cohort of patients with acute myocardial infarction (MI).
Methods:
We used follow-up data in MI survivors discharged on ticagrelor or clopidogrel enrolled in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry. The association between ticagrelor versus clopidogrel and the primary composite outcome of death, MI or stroke and the secondary outcome rehospitalisation with bleeding diagnosis at 1 year, was studied using adjusted Cox proportional hazards models, stratifying after eGFR levels.
Results:
In total, 45 206 patients with MI discharged on clopidogrel (n=33 472) or ticagrelor (n=11 734) were included. The unadjusted 1-year event rate for the composite endpoint of death, MI or stroke was 7.0%, 18.0% and 48.0% for ticagrelor treatment and 11.0%, 33.0% and 64.0% for clopidogrel treatment in patients with eGFR>60 (n=33 668), eGFR30-60 (n=9803) and eGFR<30 (n=1735), respectively. After adjustment, ticagrelor as compared with clopidogrel was associated with a lower 1-year risk of the composite outcome (eGFR>60: HR 0.87, 95% CI 0.76 to 99, eGFR30-60: 0.82 (0.70 to 0.97), eGFR<30: 0.95 (0.69 to 1.29), P for interaction=0.55) and a higher risk of bleeding (eGFR>60: HR 1.10, 95% CI 0.90 to 1.35, eGFR30-60: 1.13 (0.84 to 1.51), eGFR<30: 1.79 (1.00 to 3.21), P for interaction=0.30) across the eGFR strata.
Conclusions:
Treatment with ticagrelor as compared with clopidogrel in patients with MI was associated with lower risk for the composite of death, MI or stroke and a higher bleeding risk across all strata of eGFR. Of caution, bleeding events were more abundant in patients with eGFR<30.
Related Concept Videos
Stratified Sampling Method
To choose a stratified sample, divide the population into groups called strata and then take a...
Serum Studies: Renal Function Tests
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Classification of Epithelial Tissues: Stratified Epithelium
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...

